Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Posts Tagged ‘results’

TiVo Corporation Announces 2019 Q2 Results and Conference Call

Posted by fidest press agency su giovedì, 18 luglio 2019

TiVo Corporation (NASDAQ: TIVO) announced today that it plans to release its 2019 second quarter results on July 31, 2019. TiVo also plans to host a conference call at 5:00 p.m. ET on July 31, 2019 to discuss its financial results. Investors and analysts interested in participating are welcome to call (866) 621-1214 (or international +1-706-643-4013) and reference conference ID 8448589. The conference call may also be accessed via live webcast in the Investor Relations section of TiVo’s website at replay of the audio webcast will be available on TiVo’s website shortly after the live call ends, and we currently plan for it to remain on TiVo’s website until the next quarterly earnings call. Additionally, a telephonic replay of the call will be accessible shortly after the live call ends through August 7, 2019

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Innovus Pharma Releases Results from Annual Shareholders Meeting

Posted by fidest press agency su venerdì, 31 Mag 2019

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today released the final voting results from the Annual Shareholders Meeting held on May 28, 2019.
Votes were cast by 1,402,506 (54.3%) of the total 2,581,486 shares that were issued and outstanding on the record date of April 25, 2019, and as such were eligible to vote. The shareholders voted on four matters: (1) the re-elections of Dr. Bassam Damaj, Dr. Henry Esber, Mr. Dean Nuhaily, Ms. Vivian Liu, and Mr. Ziad Mirza to the Company’s Board of Directors, (2) the ratification of Hall and Company, Inc., as the Company’s auditors for 2019, (3) the advisory vote on the approval of compensation of the named executive officers of the Company, and (4) the approval of the Company’s 2019 Equity Incentive Plan.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights

Posted by fidest press agency su domenica, 12 Mag 2019

NEW YORK and CLEVELAND (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2019 financial results and business highlights, which will be discussed on a conference call scheduled for Tuesday, May 14 at 10:00 a.m. ET. “We’ve had a great start to 2019, with continued progress across our pipeline, including the completion of CMC work in advance of initiating our Phase 3 VITAL™ clinical trial evaluating EB-101, our gene-corrected cell therapy for patients with recessive dystrophic epidermolysis bullosa,” said João Siffert, M.D., Chief Executive Officer. “The study, which will utilize clinical material produced at our Cleveland manufacturing facility, is on track to start mid-2019 following completion of ongoing FDA review.”“We have continued to advance our lysosomal storage disease programs. Our increased efforts around patient recruitment are starting to bear fruit as we observe an uptick in patient screening for both MPS programs. In addition, we have submitted the IND for our CLN1 program.” added Dr. Siffert.First Quarter Financial Results:
Cash, cash equivalents and marketable securities as of March 31, 2019 were $68.3 million, compared to $85.0 million as of December 31, 2018. The decrease in cash of $16.7 million was driven primarily by the net cash used for operating activities of $15.1 million.
Research and development expenses for the first quarter ended March 31, 2019 were $11.7 million, compared to $8.2 million for first quarter 2018. The increase in research and development expense was primarily attributable to increased R&D headcount, related facility costs and internal manufacturing costs.
General and administrative expenses for the first quarter ended March 31, 2019 were $5.7 million, compared to $2.9 million for the first quarter 2018. The increase in general and administrative expenses was primarily attributable to increased headcount and related facility costs.
Net loss was $0.39 per share for the first quarter of 2019, compared to $0.22 per share in the same period of 2018.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

DexYP Announces Results of Tender Offer

Posted by fidest press agency su venerdì, 26 aprile 2019

DexYP®, a leading small business software provider, announced today the results of its tender offer, which previously expired at 10:00 a.m. Eastern Time on April 23, 2019 (the “Expiration Date”).DexYP raised new credit facilities in late 2018, and early 2019, the funds from which could be used for a variety of uses, including to launch a tender offer. On March 25, 2019 DexYP launched a tender offer to purchase up to 42,650,000 shares of common stock of DexYP (“Shares”) and up to 2,780,000 in vested and unexercised options to purchase Shares (“Options”) at $10.15 per Share and/or Option for an aggregate purchase price of $461,114,500.Following the Expiration Date, DexYP has reviewed the results of the tender offer, which was oversubscribed. Accordingly, DexYP has decided, pursuant to the terms of the tender offer, to exercise its right to accept for repurchase additional Share and Options up to 2% of the outstanding shares of Common Stock on a fully diluted basis, in each case on a pro rata basis. In total DexYP, accepted for repurchase (i) 43,114,970 Shares for up to $437,616,946 in aggregate value and (ii) 4,186,891 Options for up to $42,496,944 in aggregate value, for an aggregate value for both Shares and Options of up to $480,113,890, which repurchase shall be subject to adjustment to avoid the purchase of fractional Shares and/or Options (and shall be undertaken on a pro rata basis). The tender offer was oversubscribed and the Shares and Options were accepted, pursuant to the terms of the tender offer (a) subject to proration and (b) increased to reflect the Company’s decision to exercise its right pursuant to the terms of the tender offer to accept for repurchase additional Shares and Options up to 2% of the outstanding shares of Common Stock on a fully diluted basis, in each case on a pro rata basis.
Payment for the properly tendered Shares and Options that were accepted for purchase is expected to commence in the first week of May. Following the transaction, the amount of DexYP common stock outstanding is anticipated to be reduced from 103,196,920 shares to 60,081,950, subject to adjustment to avoid the purchase of fractional Shares and/or Options.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Results of The Semi-Final Allocation Draw at the Tel Aviv Museum of Art

Posted by fidest press agency su venerdì, 1 febbraio 2019

Tel Aviv. The Semi-Final Allocation Draw and the Host City Insignia Handover Ceremony marked the first official Eurovision 2019 event in Tel Aviv. The Ceremony was held at the Tel Aviv Museum of Art, one of Israel’s leading art and culture institutions, in the presence of The Mayor of Tel Aviv-Yafo, Ron Huldai, The Deputy Mayor of Lisbon, Duare Cordeiro, The Executive Supervisor of the Eurovision Song Contest, Jon-Ola Sand and the Director General of KAN, Eldad Koblenz.The event opened with the handing over of the Host City insignia from last year’s hosts, Lisbon to this year’s Host City, Tel Aviv. It is a Eurovision tradition for each Host City to add an iconic insignia to the key chain, before handing over the entire collection of insignia to the next host city.After the handing over of the Host City Insignia, the Semi-Final Allocation Draw took place, determining the order of appearance in the two semi-finals of the Eurovision Song Contest, which will take place at EXPO Tel Aviv on the 14th and 16th of May. Countries will compete for a place in the Eurovision Song Contest Finals, which will take place on Saturday, May 18th.The first part of the draw determined in which Semi-Final each of the six pre-qualified ‘Big Five’ countries (France, Germany, Italy, Spain, the United Kingdom) and host country Israel will vote.The second draw then decided in which Semi-Final each of the other participating countries will perform. The 36 Semi-Finalists were allocated into six pots, based on historical voting patterns as calculated by the contest’s official televoting partner Digame.At the request of Swiss broadcaster SRF, and following approval from the Reference Group, the governing body of the Eurovision Song Contest, Switzerland will participate in the Second Semi-Final on Thursday the 16th of May.

Posted in Estero/world news, Mostre - Spettacoli/Exhibitions – Theatre | Contrassegnato da tag: , , | Leave a Comment »

FLEETCOR Technologies to Announce Second Quarter 2018 Results on August 2, 2018

Posted by fidest press agency su martedì, 24 luglio 2018

FLEETCOR Technologies, Inc. (NYSE:FLT), today announced that the Company will host a conference call to discuss second quarter financial results on Thursday, August 2, 2018 at 5:00 pm ET. Hosting the call will be Ron Clarke, chief executive officer, Eric Dey, chief financial officer and Jim Eglseder, investor relations. A press release with second quarter financial results will be issued after the market close that same day. The conference call can be accessed live over the phone by dialing (877) 407-0784, or for international callers (201) 689-8560. A replay will be available one hour after the call and can be accessed by dialing (844) 512-2921 or (412) 317-6671 for international callers; the conference ID is 13681872. The replay will be available until Thursday, August 9, 2018. The call will be webcast live from the Company’s investor relations website at Technologies (NYSE:FLT) is a leading global provider of commercial payment solutions. The Company helps businesses of all sizes better control, simplify and secure payment of their fuel, toll, lodging and other general payables. With its proprietary payment acceptance networks, FLEETCOR provides affiliated merchants with incremental sales and loyalty. FLEETCOR serves businesses, partners and merchants in North America, Latin America, Europe, and Australasia. For more information, please visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Boston Properties to Release Second Quarter 2018 Financial Results

Posted by fidest press agency su domenica, 22 luglio 2018

Boston Properties, Inc. (NYSE: BXP), one of the largest public owners and developers of office buildings in the United States, announced today that it will release financial results for the Second Quarter of 2018 on Tuesday, July 31, 2018 after the close of trading on the New York Stock Exchange. The Company will host a conference call and audio webcast, both open to the general public, at 10:00 A.M. Eastern Time on Wednesday, August 1, 2018 to discuss the financial results for the Second Quarter and provide a Company update. The conference call can be accessed by dialing 877-706-4503 (Domestic) or 281-913-8731 (International) and entering the passcode 6696808. The replay will be available through August 22, 2018 by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering the passcode 6696808. There will also be a live audio webcast of the call, which may be accessed in the Investor Relations section of the Company’s website at Shortly after the call, a replay of the webcast will be available in the Investor Relations section of the Company’s website and archived for up to twelve months following the call.Boston Properties is a fully integrated real estate investment trust that develops, redevelops, acquires, manages, operates and owns a diverse portfolio of primarily Class A office space totaling 50.3 million square feet and consisting of 167 office properties (including eight properties under construction), six residential properties (including four properties under construction), five retail properties and one hotel. The Company is one of the largest public owners and developers of Class A office properties in the United States, concentrated in five markets – Boston, Los Angeles, New York, San Francisco and Washington, DC.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

Posted by fidest press agency su domenica, 15 luglio 2018

Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018. Pulse Biosciences management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Pulse Biosciences is a publicly listed clinical stage electroceutical company pursuing multiple clinical applications of its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation (NPS) is a non-thermal, precise, focal tissue treatment technology comprised of nanosecond (billionth of a second) range pulsed electric fields that directly affect the cell membrane and intracellular structures and initiates cell death in treated cells. The initiation of cell death by NPS results in a minimal inflammatory response, which improves healing outcomes and supports the replacement of treated tissue cells with healthy tissue cells. NPS’ unique mechanism of action to initiate cell death has the potential to significantly benefit patients for multiple medical applications in dermatology, immune-oncology, and in other unique tissue targets. In cancerous lesions, NPS has been shown in preclinical models to induce immunogenic cell death (ICD), which exposes the unique antigens of the treated cells to the immune system and enrolls immune system cells, such as cytotoxic T-cells to mount an adaptive immune response. More information is available at

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

OFG Bancorp to Report 2Q18 Results and Hold Call on Friday, July 20, 2018

Posted by fidest press agency su sabato, 30 giugno 2018

OFG Bancorp (NYSE:OFG) will report second quarter 2018 financial results Friday, July 20, 2018 before the market opens and hold its conference call that morning at 10:00 AM ET.
The call will be accessible live via a webcast on OFG’s website at A replay will be available shortly thereafter. Access the webcast link in advance to download any necessary software.Now in its 54th year in business, OFG Bancorp is a diversified financial holding company that operates under U.S. and Puerto Rico banking laws and regulations. Its three principal subsidiaries, Oriental Bank, Oriental Financial Services and Oriental Insurance, provide a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico. Investor information can be found at

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

HomeStreet Announces Preliminary Results from Annual Meeting

Posted by fidest press agency su lunedì, 28 Mag 2018

HomeStreet, Inc. (Nasdaq:HMST) (the “Company” or “HomeStreet”), the parent company of HomeStreet Bank, today announced that based on the preliminary vote count at the Company’s 2018 Annual Meeting reviewed by its proxy solicitor, all three of the Company’s director nominees, Scott M. Boggs, Douglas I. Smith and Mark R. Patterson, have been reelected to the Company’s Board of Directors. HomeStreet previously indicated that, despite the substantial risk that votes on Roaring Blue Lion’s blue proxy cards would be considered invalid under Washington State banking law, the Company would count votes on blue proxy cards on a provisional basis, subject to the final determination as to the validity of the blue proxy cards. Notably, whether or not votes on blue proxy cards are counted, all of the Board’s nominees were reelected by a majority of the votes cast and all of the Company’s proposals have been approved. Mark K. Mason, President and CEO of HomeStreet, said, “On behalf of the entire Board and management team, I would like to thank our shareholders for their support, as well as the highly valuable input they provided during this process. Our focus at HomeStreet continues to be on executing against our clear strategic plan in order to further diversify our business and deliver shareholder value.“In addition, we are committed to translating the feedback we have received from our shareholders into action. We will continue to evaluate our board composition and corporate governance policies to ensure that we are taking the right steps to position the Company for success. We also appreciate the willingness of our shareholders to engage with the Company in discussing our governance practices over the course of the coming year following proxy season. Most importantly, we look forward to further dialogue with our shareholders – as well as our customers, employees and partners – around how best to maximize the potential of HomeStreet moving forward.” The preliminary voting results also indicate that shareholders approved all other proposals considered at the Company’s 2018 Annual Meeting, including the advisory vote (non-binding) to approve executive compensation, proposal on the advisory (non-binding) vote on the frequency of future advisory shareholder votes on executive compensation and the advisory non-binding ratification of the appointment of the Company’s independent registered public accounting firm. The Company will file the voting results, as tabulated by the independent Inspector of Elections, on a Form 8-K with the Securities and Exchange Commission within four business days.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Telaria To Announce First Quarter 2018 Results on May 7, 2018

Posted by fidest press agency su giovedì, 3 Mag 2018

Telaria (NYSE:TLRA), a leading video monetization software company, will announce financial results for the first quarter ended March 31, 2018 on Monday May 7, 2018.The Company will host a conference call at 8:00 AM Eastern Time on that date. A press release will be available on the Company’s website prior to the call.Interested parties are invited to listen to the webcast on Telaria’s Investor Relations website at The conference call can also be accessed toll-free at (877) 407-9039 or (201) 689-8470 (Toll/International).Following completion of the call, a recorded replay of the webcast will be available on Telaria’s website. To listen to the telephone replay, call toll-free (844) 512-2921 or (412) 317-6671 (Toll/International), replay Pin #: 13678445. The telephone replay will be available from 11:00 AM ET May 7, 2018 through 11:59 PM ET May 14, 2018.
Telaria (NYSE:TLRA) is the leading independent data-driven software platform built to monetize and manage premium video inventory with the greatest speed, control, and transparency, wherever and however audiences are watching.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Cerus to Release First Quarter 2018 Results on May 8, 2018

Posted by fidest press agency su lunedì, 30 aprile 2018

Cerus Corporation (Nasdaq:CERS) announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
To access the live webcast, please visit the Investor Relations page of the Cerus website at
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Quidel to Hold First Quarter 2018 Financial Results Conference Call on May 8, 2018

Posted by fidest press agency su sabato, 28 aprile 2018

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2018 financial results after market close on Tuesday, May 8, 2018.Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference call, the company will also discuss business and financial developments and trends. The company’s statements may contain or constitute material information that has not been previously disclosed.To participate in the live call by telephone from the U.S., dial 877-930-5791, or from outside the U.S., dial 253-336-7286, and enter the audience pass code 347-4405. A live webcast of the call can be accessed on the Investor Relations section of the Quidel website ( The website replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on May 8, 2018 by dialing 855-859-2056 from the U.S., or by dialing 404-537-3406 for international callers, and entering pass code 347-4405.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Report positive results from two double-blind

Posted by fidest press agency su domenica, 15 aprile 2018

Soterix Medical Inc (SMI) is pleased to report positive results from two double-blind, sham-controlled clinical trials of its proprietary transcranial Direct Current Stimulation-Limited Total Energy (tDCS-LTE) technology for the treatment of depression. The Depression tDCS-LTE system is unique in providing drug-free therapy with minimal side effects while maximizing energy delivery to the dorsolateral prefrontal cortex (DLPFC) region, which is implicated in depression control.
The first clinical trial reported tDCS-LTE was an effective, safe, and tolerable add-on intervention in patients with type I or II bipolar disorder in a major depressive episode and receiving a stable pharmacologic regimen. In this 59 patient randomized, sham-controlled, double-blind trial, tDCS-LTE produced an average 14-point improvement in Hamilton Depression Rating Scale (HDRS-17) scores, after just 12 treatments. The benefit persisted for over a month, with common side-effects no different than placebo. The results of the “Bipolar Depression Electrical Treatment Trial [BETTER]” were published in JAMA Psychiatry.The second clinical trial reported tDCS-LTE to be superior to placebo producing an average 8 point decrease in the HDRS-17 after 15 consecutive weekdays of treatment (the induction phase), followed by 7 weekly treatments (the taper phase). In this 245 patient double-blind trial, patients received tDCS-LTE plus oral placebo, sham tDCS-LTE plus escitalopram (an SSRI drug), or sham tDCS-LTE plus oral placebo. The tDCS-LTE group had higher rates of itching or tingling, tinnitus, and nervousness than the other groups. The drug group side-effects included sleeplessness and severe constipation. At the trial endpoint, as the tDCS-LTE dose was tapered to weekly while escitalopram was maintained at a high daily dose, patients who received tDCS-LTE maintained significantly improved HDRS-17 scores compared to placebo while patients on high-dose escitalopram had slightly more improved HDRS-17 with noted side-effects. The results of the “ELECT-tDCS” trial were published in New England Journal of Medicine.
Physicians in the EU, Singapore, Australia, and Brazil interested in providing Soterix Medical Depression tDCS-LTE therapy are eligible for the Soterix Medical’s Partnership program which includes support on the entire patient treatment pipeline, hands-on training and staff certification, and connection to our network of physician researchers.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Viacom Inc. to Report Quarterly Financial Results on April 25, 2018

Posted by fidest press agency su giovedì, 12 aprile 2018

Viacom Inc. (NASDAQ: VIAB, VIA) announced today that on Wednesday, April 25, 2018, it will issue financial results for the quarter ending March 31, 2018. The company will conduct a conference call at 8:30 a.m. (ET), following the release of its earnings announcement.A live audio webcast of the call will be on the Investor Relations home page of Viacom’s website, beginning at 8:30 a.m. (ET) on April 25. The conference call can also be accessed by dialing 888-715-0404 (domestic) or 918-398-8248 (international). Please call five minutes in advance to ensure that you are connected prior to the call.An audio replay of the call will be available beginning at 12:00 p.m. (ET) on April 25 in the Events/Webcasts section of Viacom’s website, and at 800-585-8367 or 404-537-3406.The earnings release and any other information related to the call will be accessible from the home page of Viacom’s website.
Viacom is home to premier global media brands that create compelling entertainment content – including television programs, motion pictures, short-form content, games, consumer products, podcasts, live events and social media experiences – for audiences in 183 countries. Viacom’s media networks, including Nickelodeon, Nick Jr., MTV, BET, Comedy Central, Paramount Network, VH1, TV Land, CMT, Logo, Channel 5 (UK), Telefe (Argentina), Colors (India) and Paramount Channel, reach approximately 4.3 billion cumulative television subscribers worldwide. Paramount Pictures is a major global producer and distributor of filmed entertainment. Paramount Television develops, finances and produces original programming for television and digital platforms.
For more information about Viacom and its businesses, visit Keep up with Viacom news by following Viacom’s blog at and Twitter feed at

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Western Union to Release First Quarter Results on May 1, 2018

Posted by fidest press agency su martedì, 10 aprile 2018

The Western Union Company (NYSE: WU) announced today that Hikmet Ersek, President and CEO, and Raj Agrawal, Executive Vice President and CFO, will host a webcast and conference call to discuss first quarter 2018 results on May 1, 2018 at 4:30 p.m. Eastern time. A press release highlighting the financial results will be issued at approximately 4:00 p.m. Eastern time the same day.
The Western Union Company (NYSE: WU) is a leader in global payment services. Together with its Vigo, Orlandi Valuta, Pago Facil and Western Union Business Solutions branded payment services, Western Union provides consumers and businesses with fast, reliable and convenient ways to send and receive money around the world, to send payments and to purchase money orders. As of December 31, 2017, the Western Union, Vigo and Orlandi Valuta branded services were offered through a combined network of over 550,000 agent locations in 200 countries and territories and over 150,000 ATMs and kiosks, and included the capability to send money to billions of accounts. In 2017, The Western Union Company completed 276 million consumer-to-consumer transactions worldwide, moving $82 billion of principal between consumers, and 547 million business payments. For more information, visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call

Posted by fidest press agency su mercoledì, 21 marzo 2018

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company’s 2017 financial results.
The dial-in numbers to access the conference call are 866-300-4091 for domestic callers and 703-736-7433 for international callers. The conference ID is 7082747. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

Posted in Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Global Smoking Survey Findings To Be Presented Via Webcast

Posted by fidest press agency su giovedì, 15 marzo 2018

Media worldwide are invited to attend a press event announcing the results of the 2018 State of Smoking Survey, a study commissioned by the Foundation for a Smoke-Free World that aims to better understand why people smoke, what motivates smokers to want to quit, and what makes quitting difficult. It also seeks to find commonalities and differences among smokers worldwide to help shape the development of better approaches for tobacco harm reduction and smoking cessation across diverse cultures and economic conditions.
The international research organization Kantar conducted qualitative and quantitative interviews with 17,421 smokers, ex-smokers and non-smokers in Brazil, France, Greece, India, Israel, Japan, Lebanon, Malawi, New Zealand, Russia, South Africa, United Kingdom and United States. The survey findings will be presented on March 19, 2018 at 10:00 a.m. EDT via live webcast. Media will have an opportunity to ask questions.The World Health Organization (WHO) states that there are one billion smokers worldwide and 7.2 million deaths from smoking each year. By uncovering key drivers behind why people smoke and main barriers to quitting, the Foundation hopes to advance innovative approaches to help smokers quit or switch to reduced-harm products. These approaches will aim to more rapidly and effectively eliminate smoking around the world, hence reduce smoking-related harm and deaths.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Reductive Augmentation Results in Rounder Appearance After Breast Reduction

Posted by fidest press agency su mercoledì, 22 novembre 2017

san carlos californiaIn a just published study in Aesthetic Plastic Surgery by Paul Chasan, MD, FACS, founder of Ranch and Coast Plastic Surgery in Del Mar, CA, reductive augmentation is demonstrated to be the best choice for women who want a higher and more round breast after breast reduction surgery. Although the procedure had been done by Dr. Chasan for many years, it underwent a variety of modifications. The study represents the technique in its most recent form. See the study here.Breast reduction results in a high level of patient satisfaction. Multiple generations of the technique have resulted in better shape, less scars and more predictable results. However, even with the most proficient and technically advanced breast reductions, there continue to be limitations with respect to the shape of the breast. With time, there is almost always a lack of superior pole fullness (roundness and fullness of the upper part of the breast).“Historically, most breast reduction procedures are prone to bottoming out and lack upper pole fullness,” said Dr. Chasan. “In this article, I review breast shape classifications and describe a one-stage technique for breast reduction combined with breast augmentation called reductive augmentation to solve the problem.” He added that for women who want their large breasts reduced, adding implants during the surgical procedure seems counter-intuitive. But when breast tissue is removed without adding implants, breasts can sag as time goes on. This technique is also extremely useful for correcting breast asymmetry, as well as revising significant pseudoptosis (drooping of the bottom of the breast) in the patient who has previously undergone breast augmentation with or without mastopexy (sagging breasts).
For the study, thirty-five patients underwent reductive augmentation, of which 12 were primary surgeries, and 23 were revisions. There was an average tissue removal of 255 and 227 g, respectively, per breast for the primary and revision groups. Six of the reductive augmentations were performed for gross asymmetry. Fourteen patients had a previous mastopexy, and three patients had a previous breast reduction. The average follow-up was 26 months.“The goal of the study was to demonstrate reductive augmentation is an effective one-stage method for achieving a more round-appearing breast with upper pole fullness, both in primary breast reduction candidates and in revisionary breast surgery,” Dr. Chasan said. “For breast reduction patients who desire smaller breasts and also want rounder, ‘perkier’ breasts, reductive augmentation will provide the best possible results.” He said that this technique can also be applied to those patients with significant asymmetry.The reductive augmentation procedure takes about four hours and is performed on an outpatient basis. Most of Dr. Chasan’s reductive breast augmentation patients are up and about within three to four days after surgery.Dr. Chasan is double board-certified (plastic surgery and general surgery) and is a member of the American Society of Plastic Surgeons. He is a diplomate of the American College of Surgeons and is on the medical staff at Scripps Memorial Hospital, La Jolla, California. Dr. Chasan has written many clinical papers in peer reviewed journals, and he has innovated several surgical techniques. He regularly lectures to other plastic surgeons on the field of revisionary breast surgery for Allergan, the company that makes breast implants.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Clinical trial rules should protect patients and results not operational details

Posted by fidest press agency su giovedì, 9 marzo 2017

Sophia Antipolis. Rules governing the conduct of clinical trials are failing to produce the intended benefits for patients and should be rewritten through a transparent process that involves academic clinical trialists and patient advocates as well as regulators and industry representatives, according to recommendations published today in European Heart Journal. The call comes from the Cardiovascular Round Table (CRT), an independent forum of the European Society of Cardiology (ESC), which convened regulators, drug companies, academic clinical trialists and patients to discuss the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. “Well conducted randomised clinical trials are the bedrock of safe and effective, evidence-based treatment of cardiovascular disease. However, the cost and complexity of clinical trials has risen out of all proportion,” said lead author Professor Martin Landray, Professor of Medicine and Epidemiology, Clinical Trial Service Unit, University of Oxford, UK. “It means that many potential new treatments are abandoned before their efficacy has been thoroughly assessed. Furthermore, some ineffective or harmful treatments may continue to be used widely because of a lack of robust clinical trial data.” The paper argues that GCP requirements for randomised clinical trials should be based on the overarching principle of minimising issues that may materially impact the well-being of trial participants or the reliability of the results.Professor Landray said: “The emphasis on reliable results is not just for academic reasons. It’s the results that impact on the care of future patients. If a treatment really works but your trial fails to prove it then you’ve missed an opportunity. If a treatment is not safe and you miss that because your trial is too small or is badly conducted then that’s also bad for patients.” “The rules should be based on the principles, not on the operational details which will, and should change over time,” said Professor Barbara Casadei, ESC President-Elect and co-chair of the CRT. “We have no idea what technology and healthcare systems will look like in ten years. What we do know is that protecting patients and obtaining reliable results will remain a priority.” “Even today, innovative approaches to trial design, such as randomisation within the context of a large cardiovascular registry, are often thwarted by concerns about how to adhere to current GCP requirements that were written before the advent of smartphones or the widespread use of electronic healthcare records,” said Professor Landray.The current rules are determined by the ICH ( which includes a select group of regulators, for instance, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and pharmaceutical companies. It does not involve patients, scientific organisations, or academic clinical trialists. The CRT asserts that these groups have a major role to play in improving clinical trial guidelines. Indeed, previous experience, particularly in the US but also in Europe, has demonstrated the importance of effective engagement of all those involved in clinical trials, including academic and patient communities. The CRT meeting was the catalyst for MoreTrials, a public campaign “for more, better, randomised trials”, of which the ESC is an active supporter. These efforts have had some success, including signs of positive engagement from the ICH. For example, ICH has already made some helpful changes to GCP. In June 2016, Professor Landray and colleagues were invited to present the CRT’s concerns to the ICH meeting and as a result, in January 2017, the ICH launched a consultation on a proposal for more widespread revisions to its key guidelines.Professor Landray said: “We are delighted that the ICH is starting to listen but there is still a way to go. The ICH has proposed only limited academic engagement in the development of new GCP guidelines (largely confining our input to studies that are observational or based on existing databases).”Professor Casadei concluded: “The ESC will continue to campaign for much greater engagement between regulators, pharmaceutical companies, patients, scientific organisations and academic organisations in the development and application of clinical trials regulations. Such work is critical to advances in care and improvements in outcomes for patients with cardiovascular disease”

Posted in Estero/world news, Medicina/Medicine/Health/Science, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »